The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization
Open accessAbstract
BACKGROUND: The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has not been delineated. METHODS: In this double-blind, randomized trial, in a primary analysis involving 7243 patients under the age of 75 years receiving aspirin, we evaluated up to 30 months of treatment with prasugrel (10 mg daily) versus clopidogrel (75 mg daily). In a secondary analysis involving 2083 patients 75 years of age or older, we evaluated 5 mg of prasugrel versus 75 mg of clopidogrel. RESULTS: At a median follow-up of 17 months, the primary end point of death from cardiovascular causes, myocardial infarction, or stroke among patients under the age of 75 years occurred in 13.9% of the prasugrel group and 16.0% of the clopidogrel group (hazard ratio in the prasugrel group, 0.91; 95% confidence interval [CI], 0.79 to 1.05; P=0.21). Similar results were observed in the overall population. The prespecified analysis of multiple recurrent ischemic events (all components of the primary end point) suggested a lower risk for prasugrel among patients under the age of 75 years (hazard ratio, 0.85; 95% CI, 0.72 to 1.00; P=0.04). Rates of severe and intracranial bleeding were similar in the two groups in all age groups. There was no significant between-group difference in the frequency of nonhemorrhagic serious adverse events, except for a higher frequency of heart failure in the clopidogrel group. CONCLUSIONS: Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed. (Funded by Eli Lilly and Daiichi Sankyo; TRILOGY ACS ClinicalTrials.gov number, NCT00699998.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to their initial events, such patients are at substantial risk for recurrent, potentially fatal events.”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [5]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citationCox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
A Prospective Natural-History Study of Coronary Atherosclerosis
Stone, G. W., Maehara, A., Lansky, A. J., Bruyne, B. D., Cristea, E., Mintz, G. S., Mehran, R., McPherson, J., Farhat, N. Z., Marso, S. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1002358 · Cited by 3,301
Authors Task Force Members, Hamm, C. W., Bassand, J., Agewall, S., Bax, J. J., Boersma, E. H., Bueno, H., Caso, P., Dudek, D., Gielen, S., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr236 · Cited by 3,096
Self-citationClopidogrel for Coronary Stenting
Gurbel, P. A., Bliden, K. P., Hiatt, B. L., & O’Connor, C. M. (2003) · Circulation · doi:10.1161/01.cir.0000072771.11429.83 · Cited by 1,544
Self-citationHamm, C. W., Bassand, J., Agewall, S., Bax, J. J., Boersma, E. H., Bueno, H., Caso, P., Dudek, D., Gielen, S., Huber, K., et al. (2012) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2011.11.006 · Cited by 1,062
Self-citationThrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Tricoci, P., Huang, Z., Held, C., Moliterno, D. J., Armstrong, P. W., de Werf, F. V., White, H. D., Aylward, P. E., Wallentin, L. C., Chen, E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109719 · Cited by 756
Self-citationWright, R. S., Anderson, J. L., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Jneid, H. M., Lincoff, A. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.011 · Cited by 513
Roe, M. T., Messenger, J. C., Weintraub, W. S., Cannon, C. P., Fonarow, G. C., Dai, D., Chen, A. Y., Klein, L. W., Masoudi, F. A., McKay, C. R., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.008 · Cited by 447
Self-citation
Cited by
Sorted by citations
Items 301–400 of 873
Piccolo, R., Galasso, G., Luca, G. D., Parodi, G., Antoniucci, D., Esposito, G., Trimarco, B., & Piscione, F. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.02.024 · Cited by 17
New antiplatelet agents in the treatment of acute coronary syndromes
Sabouret, P. F., & Taiel-Sartral, M. (2014) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2014.01.009 · Cited by 17
Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome
Berger, J. S. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0291-2 · Cited by 17
Self-Powered Microfluidic Device for Rapid Assay of Antiplatelet Drugs
Jose, B., McCluskey, P., Gilmartin, N. T., Somers, M., Kenny, D. J., Ricco, A. J., Kent, N. J., & Basabe‐Desmonts, L. (2016) · Langmuir · doi:10.1021/acs.langmuir.5b03540 · Cited by 17
Zhu, H., Xu, X., Fang, X., Fei, Y., Song, L., Gao, B., Tong, G., Zhou, L., Chen, T., & Huang, J. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019184 · Cited by 17
The future of P2Y12 receptor antagonists
Thomas, M. R., & Storey, R. F. (2015) · Platelets · doi:10.3109/09537104.2015.1049519 · Cited by 16
P2Y12receptor inhibitors for secondary prevention of ischemic stroke
Liu, F., Tantry, U. S., & Gurbel, P. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1035256 · Cited by 17
Self-citationHagström, E., Roe, M. T., Hafley, G. E., Neely, M. L., Sidhu, M. S., Winters, K. J., Prabhakaran, D., White, H. D., Armstrong, P. W., Fox, K. A. A., et al. (2016) · Clinical Cardiology · doi:10.1002/clc.22533 · Cited by 16
Self-citationThe underutilisation of dual antiplatelet therapy in acute coronary syndrome
Anastasius, M. O., Lau, J. K., Hyun, K. K., D'Souza, M. I., Patel, A. A., Rankin, J. M., Walters, D., Juergens, C., Aliprandi‐Costa, B., Yan, A. T.-K., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.04.077 · Cited by 16
Self-citationBasra, S. S., Virani, S. S., Paniagua, D. E., Kar, B., & Jneid, H. M. (2015) · Heart Failure Clinics · doi:10.1016/j.hfc.2015.08.004 · Cited by 16
Kubica, J., Adamski, P., Paciorek, P., Ładny, J. R., Kalarus, Z. F., Banasiak, W., Kochman, W., Gorący, J., Wożakowska−Kapłon, B., Navarese, E. P., et al. (2017) · Kardiologia Polska · doi:10.5603/kp.a2017.0057 · Cited by 16
Prevention of Vascular Complications in Diabetes Mellitus Patients: Focus on the Arterial Wall
Lunder, M., Janić, M., & Šabović, M. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180206113755 · Cited by 18
Acute Coronary Syndrome: Focus on Antiplatelet Therapy
Bobadilla, R. V. (2016) · Critical Care Nurse · doi:10.4037/ccn2016497 · Cited by 15
Caracciolo, A., Mazzone, P., Laterra, G., Garcia-Ruiz, V., Polimeni, A., Galasso, S., Saporito, F., Carerj, S., D’Ascenzo, F., Marquis‐Gravel, G., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8112016 · Cited by 15
Fujisaki, T., Kuno, T., Ando, T., Briasoulis, Α., Takagi, H., & Bangalore, S. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.03.009 · Cited by 15
Goodwin, N., Clare, R. M., Harrington, J., Badjatiya, A., WOJDYLA, D. M., Udell, J. A., Butler, J., Januzzi, J. L., Parikh, P. B., James, S. K., et al. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.07.004 · Cited by 15
Self-citationGender differences in efficacy and safety of antiplatelet strategies for acute coronary syndromes
Occhipinti, G., Greco, A., Angiolillo, D. J., & Capodanno, D. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2245331 · Cited by 16
Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon?
Oprea, A. D., & Popescu, W. M. (2013) · Cardiology Research and Practice · doi:10.1155/2013/195456 · Cited by 16
Lópes, R. D., Leonardi, S., Neely, B., Neely, M. L., Ohman, E. M., Ardissino, D., Hamm, C. W., Goodman, S. G., Bhatt, D. L., White, H. D., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.034 · Cited by 15
Self-citationEvolving pattern of platelet P2Y12inhibition in patients with acute coronary syndromes
Joshi, R. R., Hossain, R., Morton, A. C., Ecob, R., Judge, H. M., Wales, C., Walker, J. V., Karunakaran, A., & Storey, R. F. (2013) · Platelets · doi:10.3109/09537104.2013.836175 · Cited by 14
Switching from clopidogrel to prasugrel in patients having coronary stent implantation
Parodi, G., Luca, G. D., Bellandi, B., Comito, V., Valenti, R., Marcucci, R., Carrabba, N., Migliorini, A., Ramazzotti, E., Gensini, G. F., et al. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-1040-7 · Cited by 14
Janzon, M., James, S. K., Cannon, C. P., Storey, R. F., Mellström, C., Nicolau, J. C., Wallentin, L. C., & Henriksson, M. (2014) · Heart · doi:10.1136/heartjnl-2014-305864 · Cited by 14
Self-citationRossington, J. A., Brown, O. I., & Hoye, A. (2016) · Open Heart · doi:10.1136/openhrt-2015-000296 · Cited by 16
Husted, S., & Boersma, E. H. (2015) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000237 · Cited by 14
Johnston, S. (2015) · Dental Update · doi:10.12968/denu.2015.42.9.840 · Cited by 14
Bykov, K., Schneeweiß, S., Glynn, R. J., Mittleman, M. A., Bates, D. W., & Gagne, J. J. (2017) · Drug Safety · doi:10.1007/s40264-017-0556-8 · Cited by 14
Lee, J. M., Jung, J.-H., Park, K. W., Shin, E., Oh, S. K., Bae, J., Rhew, J. Y., Lee, N., Kim, D., Kim, U., et al. (2015) · Trials · doi:10.1186/s13063-015-0925-5 · Cited by 14
ADP-Receptor Inhibitors in the Perioperative Period: The Good, the Bad, and the Ugly
Oprea, A. D., & Popescu, W. M. (2013) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2012.11.014 · Cited by 14
Risk stratification of patients undergoing medical therapy after coronary angiography
Bettinger, N., Palmerini, T., Caixeta, A. M., Dressler, O., Litherland, C., Francese, D. P., Giustino, G., Mehran, R., Leon, M. B., Stone, G. W., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv674 · Cited by 14
Galli, M., Porto, I., Andreotti, F., D’Amario, D., Vergallo, R., Bona, R. D., & Crea, F. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.10.087 · Cited by 14
Advances in Antiplatelet and Anticoagulant Therapies for NSTE-ACS
Badjatiya, A., & Rao, S. V. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1090-3 · Cited by 15
for the DOSAPI investigators., Collet, J., Hulot, J., Abtan, J., Anzaha, G., Kernéis, M., Silvain, J., Cayla, G., O’Connor, S. A., Barthélémy, O., et al. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1710-1 · Cited by 13
Ткачева, О. Н., Vorobyeva, N. M., Kotovskaya, Y. V., Рунихина, Н. К., Strazhesko, I. D., Вадимовна, В. С., Drapkina, O. M., Komarov, A. L., Orlova, Y. A., Панченко, Е. П., et al. (2021) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2021-2847 · Cited by 14
y, P. A., Bayés‐Genís, A., de Isla, L. P., Sanchís, J. M., & Heras, M. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2012.09.003 · Cited by 13
The Year in Cardiology 2012: acute coronary syndromes
West, N. E. J. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs462 · Cited by 13
Bernlochner, I., Mayer, K., Morath, T., Orban, M., Schulz, S., Schömig, A., Braun, S., Kastrati, A., & Sibbing, D. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-08-0552 · Cited by 13
Desai, R. J., Spoendlin, J., Mogun, H., & Gagne, J. J. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2018 · Cited by 13
Castini, D., Persampieri, S., Cazzaniga, S., Ferrante, G., Centola, M., Lucreziotti, S., Salerno‐Uriarte, D., Sponzilli, C., & Carugo, S. (2017) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944717738911 · Cited by 13
Associations of osteopontin and NT-proBNP with circulating miRNA levels in acute coronary syndrome
Kwee, L. C., Neely, M. L., Grass, E. A., Gregory, S. G., Roe, M. T., Ohman, E. M., Fox, K. A. A., White, H. D., Armstrong, P. W., Bowsman, L. M., et al. (2019) · Physiological Genomics · doi:10.1152/physiolgenomics.00033.2019 · Cited by 13
Self-citationBrieger, D. B., Pocock, S., Blankenberg, S., Chen, J. Y., Cohen, M. G., Granger, C. B., Grieve, R., Nicolau, J. C., Simon, T., Westermann, D., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.01.070 · Cited by 14
Self-citationCangrelor: Review of the Drug and the CHAMPION Programme (Including PHOENIX)
Marino, M., Rizzotti, D., & Leonardi, S. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0493-4 · Cited by 13
Ticagrelor Use in a Patient With a Documented Clopidogrel Hypersensitivity
Harris, J. R., & Coons, J. C. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014539143 · Cited by 13
Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges
Caterina, R. D., & Goto, S. (2016) · Vascular Pharmacology · doi:10.1016/j.vph.2016.03.003 · Cited by 13
Dual antiplatelet therapy after coronary stenting
Park, Y., Franchi, F., Rollini, F., & Angiolillo, D. J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1202924 · Cited by 13
Screever, E. M., Meijers, W. C., van Veldhuisen, D. J., & de Boer, R. A. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1316377 · Cited by 14
Selection of P2Y 12 Inhibitor in Percutaneous Coronary Intervention and/or Acute Coronary Syndrome
Tantry, U. S., Navarese, E. P., Myat, A., & Gurbel, P. A. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.01.003 · Cited by 13
Self-citationChen, H., Zhang, X., Liang, H.-B., Liu, X.-W., Zhang, X., Huang, B., & Xiu, J. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.04.054 · Cited by 13
Prasugrel versus Clopidogrel for Acute Coronary Syndromes
Roe, M. T., & Ohman, E. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1213509 · Cited by 13
Self-citationLee, P. H., Park, S., Nam, H., Kang, D., Kang, S., Lee, S., Kim, Y., Park, S., & Lee, C. W. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019637 · Cited by 12
ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction
Gibson, C. M., Chi, G., Duffy, D., Bahit, M. C., White, H. D., Korjian, S., Alexander, J. H., Lincoff, A. M., Anschuetz, G., Girgis, I. G., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.001 · Cited by 13
Self-citationHow to manage prasugrel and ticagrelor in daily practice
Bonhomme, F., Fontana, P., & Reny, J. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.01.016 · Cited by 14
Expert reviews Significance of antiplatelet therapy in emergency myocardial infarction treatment
Komosa, A., Lesiak, M., Siniawski, A., Mularek‐Kubzdela, T., & Grajek, S. (2014) · Advances in Interventional Cardiology · doi:10.5114/pwki.2014.41466 · Cited by 13
Inohara, T., Pieper, K. S., WOJDYLA, D. M., Patel, M. R., Jones, W. S., Tricoci, P., Mahaffey, K. W., James, S. K., Alexander, J. H., Lópes, R. D., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.03.013 · Cited by 12
Self-citationReid, C., AlTurki, A., Yan, A. T.-K., So, D. Y. F., Ko, D. T., Tanguay, J., Bessissow, A., Mehta, S. R., Goodman, S. G., & Huynh, T. T. (2020) · CJC Open · doi:10.1016/j.cjco.2020.02.005 · Cited by 12
Self-citationHan, S., Suzuki‐Kerr, H., Vlajkovic, S. M., & Thorne, P. R. (2022) · Purinergic Signalling · doi:10.1007/s11302-022-09896-w · Cited by 12
Jin, H., Yang, T., Choi, K.-N., Seo, J.-S., Jang, J., Kim, D.-K., & Kim, D. (2014) · Korean Circulation Journal · doi:10.4070/kcj.2014.44.2.82 · Cited by 12
Thienopyridine efficacy and cigarette smoking status
Bliden, K. P., Baker, B., Nolin, T. D., Jeong, Y., Bailey, W. L., Tantry, U. S., & Gurbel, P. A. (2013) · American Heart Journal · doi:10.1016/j.ahj.2012.12.024 · Cited by 12
Self-citationEl-Halabi, M. M., Zgheib, N. K., Mansour, N., Malli, A. H., Ghaith, O. A., Mahfouz, R. A., Alam, S., & Sharara, A. I. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31828ecf44 · Cited by 12
The discovery and development of prasugrel
Shan, J., & Sun, H. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.793668 · Cited by 12
Bossard, M., Granger, C. B., Tanguay, J., Montalescot, G., Faxon, D. P., Jolly, S. S., Widimský, P., Niemelä, K. O., Steg, P. G., Natarajan, M. K., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006577 · Cited by 12
Self-citationFITCHETT, D. H., Goodman, S. G., Leiter, L. A., Lin, P., Welsh, R. C., Stone, J. A., Grégoire, J. C., McFarlane, P. A., & Langer, A. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.03.002 · Cited by 12
Self-citationSwitching between thienopyridines in patients with acute myocardial infarction and quality of care
Schiele, F., Puymirat, É., Bonello, L., Meneveau, N. F., Collet, J., Motreff, P., Ravan, R., Leclercq, F., Ennezat, P., Ferrières, J., et al. (2016) · Open Heart · doi:10.1136/openhrt-2015-000384 · Cited by 12
Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks
Singh, M., Bhatt, D. L., Stone, G. W., Rihal, C. S., Gersh, B. J., Lennon, R. J., Narula, J., & Fuster, V. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.06.013 · Cited by 11
Self-citationTicagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial
Piccolo, R., Simonetti, F., Avvedimento, M., Cutillo, M., Canonico, M. E., Conti, V., Gargiulo, G., Paolillo, R., Piaz, F. D., Filippelli, A., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae054 · Cited by 12
Gupta, A. K., Mustafiz, C., Mutahar, D., Zaka, A., Parvez, R., Mridha, N., Stretton, B., Kovoor, J. G., Bacchi, S., Ramponi, F., et al. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.01.037 · Cited by 11
Oral antiplatelet drugs in patients with chronic kidney disease (CKD): a review
Ibrahim, H., & Rao, S. V. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1483-3 · Cited by 11
Laredo, V., Sostres, C., García, S. G., Carrera‐Lasfuentes, P., Revilla-Martí, P., & Lanas, Á. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051526 · Cited by 11
Park, K. H., Jeong, M. H., Lee, K. H., Sim, D. S., Yoon, H. J., Yoon, N. S., Kim, K. H., Park, H. W., Hong, Y. J., Kim, J. H., et al. (2013) · Journal of Cardiology · doi:10.1016/j.jjcc.2013.07.004 · Cited by 11
Pharmacokinetic and Pharmacodynamic Effects of Prasugrel in Healthy Korean Males
Yu, K., Park, K. W., Kelly, R. P., Gu, N., Payne, C. D., Small, D. S., Choi, H. C., Kawakatsu, E., & Pinton, P. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318290d9e1 · Cited by 11
Medical therapy of coronary artery disease after percutaneous intervention
Kurz, D. J., & Eberli, F. R. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.01.011 · Cited by 11
Johnston, S. (2015) · The Journal of the American Dental Association · doi:10.1016/j.adaj.2015.11.007 · Cited by 11
Chin, C. T., Neely, B., Ohman, E. M., Armstrong, P. W., Corbalán, R., White, H. D., Prabhakaran, D., Winters, K. J., Fox, K. A. A., Roe, M. T., et al. (2016) · Stroke · doi:10.1161/strokeaha.115.012454 · Cited by 11
Self-citationBleeding events and maintenance dose of prasugrel: BLESS pilot study
Carrabba, N., Parodi, G., Marcucci, R., Valenti, R., Gori, A. M., Migliorini, A., Comito, V., Bellandi, B., Abbate, R., Gensini, G. F., et al. (2016) · Open Heart · doi:10.1136/openhrt-2016-000460 · Cited by 11
Switching P2Y12 Receptor Inhibiting Therapies
Rollini, F., Franchi, F., & Angiolillo, D. J. (2016) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2016.08.006 · Cited by 11
Dalby, A. J., Gottlieb, S., Cyr, D. D., Ohman, E. M., McGuire, D. K., Rużyłło, W., Bhatt, D. L., Wiviott, S. D., Winters, K. J., Fox, K. A. A., et al. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.03.015 · Cited by 11
Self-citationTailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk
Baber, U., Leisman, D. E., Cohen, D. J., Gibson, C. M., Henry, T. D., Dangas, G., Moliterno, D. J., Kini, A. S., Krucoff, M. W., Colombo, A., et al. (2019) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.004945 · Cited by 11
Switching between P2Y12 antagonists – From bench to bedside
Gąsecka, A., Konwerski, M., Pordzik, J., Soplińska, A., Filipiak, K. J., Siller-Matula, J. M., & Postula, M. A. (2019) · Vascular Pharmacology · doi:10.1016/j.vph.2019.01.003 · Cited by 11
Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
Jain, N., Phadnis, M. A., Hunt, S. L., Dai, J., Shireman, T. I., Davis, C. L., Mehta, J. L., Rasu, R. S., & Hedayati, S. S. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.06.031 · Cited by 11
The Rationale for and Clinical Pharmacology of Prasugrel 5 mg
Jakubowski, J. A., Erlinge, D., Alexopoulos, D. K., Small, D. S., Winters, K. J., Gurbel, P. A., & Angiolillo, D. J. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0202-3 · Cited by 11
Self-citationBleeding associated with the management of acute coronary syndromes
Silva, K. D., Myat, A., Cotton, J. M., James, S. K., Gershlick, A., & Stone, G. W. (2017) · Heart · doi:10.1136/heartjnl-2015-307602 · Cited by 11
Goldstein, S. A., Newby, L. K., Cyr, D. D., Neely, M. L., Lüscher, T. F., Brown, E. B., White, H. D., Ohman, E. M., Roe, M. T., & Hamm, C. W. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005334 · Cited by 11
Self-citationLee, K. K., Welton, N. J., Shah, A. S. V., Adamson, P. D., Dias, S., Anand, A., Newby, D. E., Mills, N. L., & McAllister, D. (2017) · Heart · doi:10.1136/heartjnl-2017-312003 · Cited by 10
Verheugt, F. W. A. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht075 · Cited by 11
Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents
Parekh, P. J., Oldfield, E. C., & Johnson, D. A. (2015) · Drugs · doi:10.1007/s40265-015-0455-1 · Cited by 10
Zhang, L., Lü, J., Dong, W., Tian, H., Feng, W., You, H., He, H., Ma, J., & Dong, Y. (2016) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000451 · Cited by 10
Prognostic Implications of Dual Platelet Reactivity Testing in Acute Coronary Syndrome
de Carvalho, L. P., Fong, A. Y. Y., Troughton, R. W., Yan, B. P., Chin, C.-T., Poh, S.-C., Mejin, M., Huang, N., Seneviratna, A., Lee, C., et al. (2018) · Thrombosis and Haemostasis · doi:10.1160/th17-08-0564 · Cited by 10
Sun, Y., Lin, F., Li, X., Wang, Z., Gao, R., & Wu, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.878270 · Cited by 10
Refining the Role of Antiplatelet Therapy in Medically Managed Patients With Acute Coronary Syndrome
Boden, W. E., Lansky, A. J., & Angiolillo, D. J. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.10.018 · Cited by 10
Self-citationPiccolo, R., Gioia, G. D., Niglio, T., D’Anna, C., Rosa, R. D., Strisciuglio, T., Bevilacqua, M., Piscione, F., Cirillo, P. L., & Galasso, G. (2012) · Angiology · doi:10.1177/0003319712467530 · Cited by 10
Medical management: the dark side of acute coronary syndromes
Bueno, H. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv017 · Cited by 9
Management of elderly patients with a non-ST-segment-elevation acute coronary syndrome
Gimbel, M. E., & ten Berg, J. M. (2017) · Netherlands Heart Journal · doi:10.1007/s12471-017-1002-3 · Cited by 10
Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma
Chaturvedula, S. T., Diver, D. J., & Vashist, A. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7040074 · Cited by 11
D’Ascenzo, F., Celentani, D., Brustio, A., Grosso, A., Raposeiras‐Roubín, S., Abu‐Assi, E., Henriques, J. P. S., Saucedo, J., González‐Juanatey, J. R., Wilton, S. B., et al. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0273-4 · Cited by 10
Cordero, A., García‐Acuña, J. M., Rodríguez‐Mañero, M., Agra-Bermejo, R., Cid, B., Álvarez, B. Á., Bertomeu‐González, V., Fácila, L., Bertoméu, V., & González‐Juanatey, J. R. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.06.057 · Cited by 10
Antiplatelet Agents for Cancer Prevention: Current Evidences and Continuing Controversies
Frère, C., Lejeune, M., Kubicek, P., Faille, D., Marjanovic, Z., & Cancer, T. G. F. T. E. (2019) · Cancers · doi:10.3390/cancers11111639 · Cited by 10
Hokimoto, S., Akasaka, T., Tabata, N., Arima, Y., Tsujita, K., Sakamoto, K., Kaikita, K., Morita, K., Kumagae, N., Yamamoto, E., et al. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.03.033 · Cited by 10
New antiplatelet agents for cardiovascular disease
Chua, D., & Nishi, C. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.130033 · Cited by 11
Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes
Roffman, D. S. (2015) · Journal of Pharmacy Practice · doi:10.1177/0897190014568383 · Cited by 12
Chan, M. Y., Neely, M. L., Roe, M. T., Goodman, S. G., Erlinge, D., Cornel, J. H., Winters, K. J., Jakubowski, J. A., Zhou, C., Fox, K. A. A., et al. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.265272 · Cited by 10
Self-citationKim, M. C., Jeong, M. H., Sim, D. S., Hong, Y. J., Kim, J. H., Ahn, Y., Ahn, T. H., Seung, K. B., Choi, D., Kim, H.-S., et al. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0112 · Cited by 10
Metadata
- Authors
- Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., Ardissino, D., Nicolau, J. C., Boden, W. E., Gurbel, P. A., Ruzyllo, W., Dalby, A. J., McGuire, D. K., Leiva-Pons, J. L., Parkhomenko, A., Gottlieb, S., Topacio, G. O., Hamm, C., Pavlides, G., Goudev, A. R., Oto, A., Tseng, C.-D., Merkely, B., Gasparovic, V., Corbalan, R., Cinteză, M., McLendon, R. C., Winters, K. J., Brown, E. B., Lokhnygina, Y., Aylward, P. E., Huber, K., Hochman, J. S., & Ohman, E. M.
- Affiliations
- Duke Medical Center (US)
- University of Alberta (CA)
- Duke University (US)
- St. Michael's Hospital (CA)
- Brigham and Women's Hospital (US)
- University of Copenhagen (DK)
- National Taiwan University (TW)
- Eli Lilly (United States) (US)
- Flinders University (AU)
- ORCID
- Roe, Matthew T.
- Armstrong, Paul W.
- Fox, Keith A.A.
- White, Harvey D.
- Prabhakaran, Dorairaj
- Goodman, Shaun G.
- Cornel, Jan H.
- Bhatt, Deepak L.
- Clemmensen, Peter
- Ardissino, Diego
- Boden, William E.
- Gurbel, Paul A.
- McGuire, Darren K.
- Leiva-Pons, Jose L.
- Parkhomenko, Alexander
- Gottlieb, Shmuel
- Hamm, Christian
- Goudev, Assen R.
- Oto, Ali
- Aylward, Philip E.
- Huber, Kurt
- Hochman, Judith S.
- Ohman, E. Magnus
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-10-04
- Volume
- 367
- Issue
- 14
- Pages
- 1297-1309
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2109577952
- Cited by
- 874
- References
- 18
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 14 · 2023: 31 · 2022: 43 · 2021: 49 · 2020: 58 · 2019: 53 · 2018: 70 · 2017: 92 · 2016: 71 · 2015: 91 · 2014: 114 · 2013: 124 · 2012: 20
- FWCI
- 71.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- Trakya University's Institutional Open Access System (Trakya University) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
- ORBi (University of Liège) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Helsinn
- Boston Scientific Corporation
- Boston VA Research Institute
- Regeneron Pharmaceuticals
- Amarin Corporation
- Medicines Company
- Regado Biosciences
- Eisai
- Astellas Pharma
- Servier
- Genentech
- Janssen Pharmaceuticals
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- prasugrel, clopidogrel, acute coronary syndrome, non-ST-elevation myocardial infarction, unstable angina, platelet aggregation inhibition, antiplatelet therapy, bleeding risk, heart failure, cardiovascular mortality, stroke, elderly patients
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Angina, Unstable, Aspirin, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Thiophenes, Ticlopidine, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
